Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

Background: The estimated economic cost of Clostridioides difficile infection (CDI) is $5.4 billion annually, primarily attributed to acute-care costs. We previously reported data from ECOSPOR III that SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing recur...

Full description

Bibliographic Details
Main Authors: Stuart Cohen, Thomas Louie, Charles Berenson, Alpesh Amin, David Lombardi, Sissi Pham, Shirley Huang, Elaine Wang, Brooke Hasson, Barbara McGovern, Lisa Von Moltke
Format: Article
Language:English
Published: Cambridge University Press 2022-07-01
Series:Antimicrobial Stewardship & Healthcare Epidemiology
Online Access:https://www.cambridge.org/core/product/identifier/S2732494X22001966/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S2732494X22001966/type/journal_article

Similar Items